Safety run-in of intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN protein vaccination as treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1.
Mark H EinsteinRichard B S RodenLouise FerrallMark AkinAllison BlomerT -C WuYung-Nien ChangPublished in: Cancer prevention research (Philadelphia, Pa.) (2023)
Patients with HPV16 infection and low-grade cervical dysplasia (LSIL/CIN1) or atypical squamous cells (ASC-US/ASC-H) require active surveillance for disease progression. A safe and effective immunotherapy to clear HPV16 is an unmet medical need. The safety run-in cohort of a randomized double-blind, placebo-controlled Phase II trial of PVX2 (vaccination twice with HPV16-targeting pNGVL4a-Sig/E7(detox)/HSP70 plasmid and once with the HPV16 L2E7E6 fusion protein "TA-CIN") as immunotherapy for patients with HPV16+ ASC-US, ASC-H, or LSIL/CIN1 (NCT03911076) was recently completed. The primary objective of this cohort was to determine the safety and tolerability of PVX2 vaccination. Subjects were confirmed to have HPV16 infection and LSIL/CIN1, ASC-US, or ASC-H. Adverse events were evaluated using CTCAE v5.0. HPV typing by HPV16 18/45 Aptima Assay was done at baseline, month 6, and month 12, with simultaneous cytology analysis. Cervical biopsies and ECC were performed at baseline and month 6. In the safety run-in cohort 12 eligible patients were enrolled. Each received three monthly immunizations. One was lost to follow-up after week 12. There were no serious adverse events. A total of five adverse events were noted by four patients; 4 were considered not vaccine-related, and one 'unlikely related' by the investigator. At month 6, 45% (5/11) of participants converted to HPV16-negative and 2 others developed CIN2+ and received a LEEP. At month 12, 64% (7/11) were HPV16-negative, including those HPV16-negative at month 6. In conclusion, PVX2 immunotherapy was well tolerated and associated with viral regression, supporting further testing.
Keyphrases
- high grade
- low grade
- nlrp inflammasome
- cervical cancer screening
- end stage renal disease
- placebo controlled
- double blind
- clinical trial
- chronic kidney disease
- squamous cell carcinoma
- ejection fraction
- healthcare
- sars cov
- heat shock protein
- escherichia coli
- high throughput
- crispr cas
- cell proliferation
- peritoneal dialysis
- induced apoptosis
- oxidative stress
- single cell
- circulating tumor cells
- drug induced
- binding protein